Web7. mar 2024 · 目前化合物sph1188作为1.1类创新药物获国家食品药品监督管理总局颁发“药物临床试验批件”,获准进入i-iii期临床试验。 化合物SPH1188已获中国及美 专利保护,目前该化合物已以总计一千万人民币及专权期内药品销售净收入的1.5 %转让于上海医药集团股份有 … WebFor the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing …
Phase I, Open-label Study to Evaluate the Safety, Tolerance ...
Web21. dec 2016 · 上海医药 (601607): SPH1188-11获CFDA临床试验批件(已在美国中国注册相关专利,用于非小细胞肺癌等肿瘤治疗, 有可能成为明星产品 ). 广生堂 (300436): 与药明康德签订“治疗肝癌新药 GST-HG161”合作开发合同. Web26. apr 2016 · 摘要本周上海医药又一个1.1类化药sph1188-11进入cde审评中心,歌礼生物1.1类抗丙肝新药asc16片、广州南鑫药业1.1类抗肿瘤新药美他非尼片审评完毕。本周看点1、上海医药集团继近期1.1类化药sph3127片审评完毕之后,又一个1.1类化药sph1188-11进入排队待审评阶段;2、泰州迈博太... incarcerated children statistics
《國企紅籌》上海醫藥(2607)原化學藥品獲臨床試驗批件 - 每日 …
Web15. sep 2024 · Confirmed diagnosis of SCD (HbSS, or HbSβ0-thalassemia). Body weight ≥ 40 kg (inclusive) at Screening. Must follow protocol-specified contraception guidance while on treatment and for up to 6 months after last dose. Hemoglobin between 5.5 and 10 g/dL at Screening. Have had 1 to 10 VOCs in the past 12 months. Patients receiving hydroxyurea ... http://research.10jqka.com.cn/thssjzxhz/20160329/c588861780.shtml Web20. apr 2016 · 上海医药集团股份有限公司的化药1.1类sph1188-11原料及片剂的临床申请获受理,该药是一种egfr抑制剂,拟用于非小细胞肺癌(nsclc)等恶性肿瘤的治疗。 截至目前, … incarcerated children are still children